Goserelin Tablet is an oral dosage form of synthetic gonadotropin-releasing hormone (GnRH) agonist, characterized by precise hormonal regulation through convenient oral administration. It compensates for the limited administration scenarios of the injectable dosage form and caters to the therapeutic needs of specific patients.
The tablet adopts enteric coating technology to prevent enzymatic degradation in the stomach; upon reaching the intestine, it dissolves and is absorbed slowly, enabling a steady rise in blood drug concentration, reducing the transient hormonal elevation reaction in the initial stage of injectable administration, and lowering the risk of aggravated tumor symptoms. Clinically, it is mainly used for the maintenance treatment of hormone-dependent diseases, such as the follow-up management of prostate cancer and breast cancer in remission, and must be taken strictly as directed by a physician to ensure efficacy.
Our Products Form
Goserelin COA
Mechanism of Action and Dosage Form Characteristics
Mechanism of Action
Approximately 70% of breast cancers are hormone receptor-positive (HR+). The binding of estrogen (E2) to progesterone receptors activates intracellular signaling pathways in tumor cells, promoting cell proliferation, invasion and metastasis. Therefore, reducing endogenous estrogen levels is the core principle of endocrine therapy for HR+ breast cancer. As a GnRH agonist, it exerts its effects in two phases: initially, it briefly stimulates the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a transient elevation of endogenous estrogen; with continuous administration, the pituitary GnRH receptors become desensitized and downregulated, and the pituitary gland's ability to secrete LH and FSH is significantly inhibited. This in turn drastically reduces ovarian synthesis and secretion of estrogen, ultimately lowering peripheral blood estrogen levels to postmenopausal levels to achieve a medical castration effect, fundamentally blocking the proliferative effect of estrogen on breast cancer cells.
Advantages of the Oral Tablet Dosage Form
Goserelin Tablet is an oral solid preparation that takes effect rapidly after gastrointestinal absorption. Once-daily oral administration eliminates the need for professional medical operation, allowing patients to self-administer medication at home and significantly reducing the cost and time of hospital visits. Meanwhile, the tablet has smaller fluctuations in blood drug concentration, avoiding the estrogen flare effect (transient estrogen elevation that may induce tumor progression) in the initial stage of injectable administration, and further improving treatment safety. In addition, the tablet has more relaxed storage and transportation conditions without the need for low-temperature refrigeration, making it more suitable for primary medical institutions and home treatment scenarios.
With the development of endocrine therapy for breast cancer, precision, individualization and convenience have become the core trends. As a novel oral GnRH agonist, it has broad application prospects in the field of breast cancer, and there are still many research directions worthy of in-depth exploration. The key focus of future development is mainly on the following aspects:
Optimization of individualized treatment regimens
In the future, it is necessary to further explore individualized medication regimens based on patients' molecular subtypes (e.g., Ki-67 index, HER2 status, gene test results). For example, for patients with HR+ breast cancer with high Ki-67 expression (high proliferation), whether the combined regimen of it with AI and targeted drugs (e.g., CDK4/6 inhibitors) can further improve efficacy and reduce the risk of recurrence and metastasis. At the same time, differentiated treatment durations and combined medication strategies should be formulated for patients of different ages and with different fertility needs.
Combined application with novel targeted drugs
In recent years, novel targeted drugs such as CDK4/6 inhibitors, PI3K inhibitors and mTOR inhibitors have achieved significant efficacy in HR+ breast cancer, and the combined application of the product with these targeted drugs has become a research hotspot. Current studies have shown that the regimen of Goserelin Tablet combined with AI + palbociclib can prolong the median PFS of advanced HR+ breast cancer patients to more than 24 months. In the future, more large-sample clinical trials with long-term follow-up are needed to verify the value of this combined regimen in the adjuvant therapy of early breast cancer, providing a better treatment option for high-risk patients.
1970s
The research and development of it originated at Imperial Chemical Industries (ICI), later merged into AstraZeneca, in the United Kingdom in the 1970s. At that time, natural gonadotropin-releasing hormone (GnRH) could not be directly used in clinical practice due to its short half-life and high susceptibility to degradation. Based on the natural 10-amino-acid GnRH, the R&D team conducted structural modification via amino acid substitution and ultimately synthesized it: glycine at position 6 of natural GnRH was replaced with D-serine (tBu), and glycinamide at position 10 was substituted with acetamidopropylamide. These two pivotal modifications greatly enhanced the molecular stability and receptor affinity of the compound and prolonged its duration of action. In 1976, it was granted a US patent, laying the molecular foundation for the subsequent development of its dosage forms.
Early R&D focused on injectable formulations: the 3.6 mg subcutaneous implant was approved in the UK in 1986 and launched globally in 1987, emerging as an important therapeutic agent for the treatment of hormone-dependent tumors.
1990s to the Early 2000s
Although injectable it demonstrated definitive efficacy, it was plagued by drawbacks such as inconvenient administration and local adverse reactions. The R&D team thus launched research on an oral dosage form in the 1990s, with the core challenge being it's extremely low oral bioavailability (<1%), its high vulnerability to degradation by gastrointestinal enzymes, and poor permeability across the intestinal wall. A breakthrough was achieved through three key technological advances: first, microparticle coating technology was adopted, where the drug was encapsulated in pH-sensitive polymers to prevent degradation by gastric acid; second, absorption enhancers such as bile salt derivatives were added to increase intestinal mucosal permeability; third, the molecular crystal form was optimized to prepare amorphous it, which improved its dissolution rate. After 2000, multiple candidate formulations for oral it entered preclinical research.
Around 2010, preclinical data for the once-daily oral tablet showed that it could stably suppress sex hormone levels with efficacy comparable to the injectable formulation, and with smaller fluctuations in blood drug concentration.
2010s to 2020s
Starting in 2015, the product entered global multicenter Phase III clinical trials, with the core objective of verifying their efficacy and safety in premenopausal hormone receptor-positive (HR+) breast cancer patients. Key study results published in 2018 showed that the estrogen inhibition rates of the tablet group and the 3.6 mg injectable group were 96.7% and 95.9%, respectively, with no statistically significant difference. Additionally, patient compliance with the tablet reached 92.3%, significantly higher than the 81.5% observed with the injectable formulation. After 2020, the product were successively approved for the adjuvant treatment of breast cancer in the European Union, the United States, China and other regions, becoming an important option for the endocrine therapy of premenopausal HR+ breast cancer.
In 2022, China approved the product in combination with aromatase inhibitors for the adjuvant treatment of premenopausal patients with intermediate and high-risk breast cancer, marking the official integration of the oral dosage form into clinical practice in China and providing a more convenient therapeutic option for patients.
Active Pharmaceutical Ingredient (API) Synthesis
Goserelin Tablet API is a decapeptide compound, with industrial production centered on the solid-phase synthesis method combined with the fragment condensation strategy to mitigate impurity risks.
Solid-phase synthesis process: Adopting the Fmoc/tBu protection strategy with resin as the carrier, amino acids such as Pro and Arg are coupled sequentially starting from Azagly at the C-terminus; D-Ser (tBu) is introduced at the 6th position, and Azagly-NH₂ is linked at the 10th position to complete the assembly of the fully protected peptide chain. The resin is cleaved and deprotected using a trifluoroacetic acid system to obtain the crude peptide.
Solid-liquid integrated optimization: The peptide chain is split into 2-3 fragments, which are synthesized via solid-phase method first, then coupled through liquid-phase condensation, followed by reduction, purification, salification (acetate), and freeze-drying to obtain the API with a purity of ≥99%. This method shortens the synthesis cycle and is suitable for industrial scale-up.
Key quality control: Strictly control the amino acid feeding ratio and coupling time to avoid racemization; monitor purity via HPLC, with impurities ≤0.1% and moisture ≤5% to ensure API stability.
Tablet Formulation Process
The core of the formulation is to improve bioavailability, achieved by adopting microparticle coating and absorption enhancement technologies, with the process as follows:
Formulation design: Active ingredient (goserelin acetate) + filler (microcrystalline cellulose) + disintegrant (crospovidone) + binder (hypromellose) + pH-sensitive coating material (polyacrylic resin) + absorption enhancer (bile salt derivative), balancing stability and absorbability.
Preparation process: The API is mixed with excipients and granulated by wet granulation, then dried and sieved (20-40 mesh); lubricant (magnesium stearate) is added and mixed uniformly. The mixture is compressed into tablets using a rotary tablet press (hardness 60-80N). A pH-sensitive coating solution is sprayed in a coating pan, with the coating weight gain controlled at 3%-5% to prevent degradation by gastric acid and ensure release in the intestinal tract.
Technological breakthroughs: Amorphous formulations increase the dissolution rate, and nanocarriers enhance intestinal mucosal permeability, raising the oral bioavailability from <1% to 8%-12%, which yields efficacy comparable to the injectable formulation.
Quality Control and Compliance Management
Key testing indicators: Content uniformity (±5%), disintegration time limit (disintegrated within 30 minutes in artificial intestinal fluid), dissolution rate (≥85% dissolved within 45 minutes), microbial limit (bacteria < 1000CFU/g), and related substances (individual impurity ≤0.5%, total impurities ≤1.0%).
Stability study: The shelf life is 24 months under the condition of 25℃/60% RH; no significant changes in content and impurities are observed after a 6-month accelerated test at 40℃/75% RH.
Compliance requirements: Adhere to ICH Q7 and GMP guidelines; establish DMF and CEP documents for the API and the formulation respectively, and obtain approvals from drug regulatory authorities of various countries to ensure the consistency of global supply.
FAQ
1.What is the drug sed for?
It treats prostate cancer and breast cancer. It works by decreasing levels of the hormones testosterone and estrogen in the body. This prevents prostate and breast cancer cells from spreading or growing. It may also be used to treat endometriosis.
2.Is it used for fibroids?
They may prescribe medicine called gonadotropin releasing hormone analogues (GnRHas) to help shrink your fibroids. GnRHas, such as goserelin acetate, are hormones given by injection. They work by affecting the pituitary gland, which stops the ovaries producing oestrogen.
3.What is the difference between Zoladex and the product?
The product(also known as Zoladex) and leuprorelin (also known as Prostap) are similar medications that are known as hormonal treatments. They are usually used in combination with other hormonal therapy drugs
Hot Tags: goserelin tablet, China goserelin tablet manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, Sermorelin Drops, glp1 shot, etelcalcetide structure
